What are the gaps in current research on cannabis and nerve pain?

PostedFebruary 17, 2026

UpdatedFebruary 17, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

While interest in cannabis as a treatment for neuropathic pain has grown rapidly, there are still significant gaps in research on cannabis and nerve pain. Many studies suggest potential benefits, but the evidence remains incomplete, leaving patients and clinicians with unanswered questions.

One of the key gaps in research on cannabis and nerve pain is the lack of large-scale, long-term clinical trials. Much of the available data comes from small or short-term studies, making it difficult to fully assess safety, dosing, and consistency of outcomes. Researchers also highlight cannabis research limitations in neuropathic pain, including challenges with study design, variable formulations, and differing methods of administration.

Key Research Limitations

Below are some of the main cannabis evidence gaps in neuropathy and ongoing cannabis study challenges in nerve pain.

Limited sample sizes

Many trials involve small patient groups, reducing the strength and reliability of findings across broader populations.

Lack of standardised products

Differences in cannabis strains, THC-to-CBD ratios, and delivery methods make it difficult to compare results and establish clear treatment guidelines.

Long-term safety data

Few studies track patients over years, leaving questions about dependency, tolerance, and potential side effects unanswered.

Overall, while early findings are promising, the gaps in research on cannabis and nerve pain must be addressed before cannabis can be confidently recommended as a mainstream therapy. Expanding study sizes, standardising formulations, and monitoring long-term outcomes will be crucial for building stronger medical evidence.

If you’re exploring cannabis treatment options for neuropathic pain, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and neuropathic pain

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.